| Ytd | 222.35% | |
| 1y | 171.36% |
| Open | 101.16 | Prev Close | 102.88 | Low | 99.91 | High | 104.65 | Mkt Cap | 6.37B |
| Vol | 1.50M | Avg Vol | 1.71M | EPS | -1.32 | P/E | N/A | Forward P/E | -134.78 |
| Beta | 2.21 | Short Ratio | 9.72 | Inst. Own | 123.83% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-03 | 50-d Avg | 68.89 | 200-d Avg | 45.98 | 1yr Est | 74.10 |
TWST News
Guggenheim analyst Subbu Nambi maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the
Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and rais
https://www.sec.gov/Archives/edgar/data/1581280/000110465926075726/tm2617605-1_s3asr.htm
TD Cowen analyst Brendan Smith maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the
Canaccord Genuity analyst Kyle Mikson initiates coverage on Twist Bioscience (NASDAQ:TWST) with a
Piper Sandler analyst David Westenberg initiates coverage on Twist Bioscience (NASDAQ:TWST) with
-LenioBio GmbH, a TechBio company commercializing its ALiCE® cell-free protein expression platform,
Twist Bioscience Corp (TWST) reported Q2 loss but exceeded sales guidance. CEO expects profitability
Top Wall Street analysts changed outlook on top names. Check analyst ratings page for full changes.
Top analysts change outlooks on top names: UBS raises price target for TD Synnex, BMO Capital raises
Leerink Partners analyst Puneet Souda upgrades Twist Bioscience (NASDAQ:TWST) from Market Perform
Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and rais
Guggenheim analyst Subbu Nambi maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the
Baird analyst Catherine Ramsey maintains Twist Bioscience (NASDAQ:TWST) with a Outperform and rai
Twist Bioscience posts wider Q2 loss, beats revenue estimates, raises FY26 outlook, and expands gene
Twist Bioscience (NASDAQ:TWST) reported quarterly losses of $(0.59) per share which missed the analy
Twist Bioscience (NASDAQ:TWST) sees Q3 sales of $114.000 million-$115.000 million vs $111.371 millio
Synthesis of structurally complex and highly-engineered protein sequences to enable acceptance of ap
Twist Bioscience (NASDAQ:TWST) raises FY2026 sales outlook from $435.000 million-$440.000 million to
Evercore ISI Group analyst Vijay Kumar maintains Twist Bioscience (NASDAQ:TWST) with a Outperform
Guggenheim analyst Subbu Nambi maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the
ARK's 2025 winners included Robinhood, AMD and Palantir, while its losers were The Trade Desk, R
B-Body® platform complements Twist's antibody discovery offering enabling rapid, efficient and p
Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launc
Evercore ISI Group analyst Vijay Kumar maintains Twist Bioscience (NASDAQ:TWST) with a Outperform
Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and rais
Twist Bioscience reported Q1 results in line with expectations. Analyst remains confident in the com
For the second quarter,Twist expects Total revenue of approximately $107 million to $108 million, gr
For the full fiscal year 2026, Twist expects: Total revenue in the range of $435 million to $440
Guggenheim analyst Subbu Nambi maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the
Twist Bioscience (NASDAQ:TWST) affirms FY2026 sales outlook from $425.000 million-$435.000 million t
Fiscal 2026 First Quarter Preliminary, Unaudited Revenue Total revenue for the first quarter of fisc
TD Cowen analyst Brendan Smith maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the
Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and rais
Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and lowe